Topiramate for Migraine Prevention: A Randomized Controlled Trial

JAMA

Volumn 291, Issue 8, 2004, Pages 965-973

  Brandes, Jan Lewis ^a   Saper, Joel R ^b   Diamond, Merle ^c   Couch, James R ^d   Lewis, Donald W ^e   Schmitt, Jennifer ^f   Neto, Walter ^f   Schwabe, Stefan ^f   Jacobs, David ^f  

^a Nashville Neuroscience Group   (United States)

^b Michigan Hd Pain Neurologic Inst   (United States)

^c DIAMOND HEADACHE CLINIC   (United States)

^d UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^e CHILDREN S HOSPITAL OF THE KING S DAUGHTERS   (United States)

^f JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BICARBONATE; CHLORIDE; GABAPENTIN; IMIPRAMINE; NADOLOL; NORTRIPTYLINE; PLACEBO; PROPRANOLOL; SEROTONIN UPTAKE INHIBITOR; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID; DRUG DERIVATIVE; FRUCTOSE;

ADULT; AGED; ANOREXIA; ARTICLE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GLAUCOMA; HUMAN; HYPERESTHESIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MEMORY DISORDER; MIGRAINE; MULTICENTER STUDY; MYOPIA; NAUSEA; NEPHROLITHIASIS; NORTH AMERICA; OPEN STUDY; PARESTHESIA; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; STATISTICAL ANALYSIS; TASTE DISORDER; WEIGHT REDUCTION; ADOLESCENT; CHILD; DRUG EFFECT; MIDDLE AGED; STATISTICAL MODEL;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; CHILD; DOUBLE-BLIND METHOD; FEMALE; FRUCTOSE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; WEIGHT LOSS;

EID: 1442359548     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.291.8.965     Document Type: Article

References (35)

1. Terwindt GM, Ferrari MD, Tijhuis M, Groenen SM, Picavet HS, Launer LJ. The impact of migraine on quality of life in the general population: the GEM study. Neurology. 2000;55:624-629.
2. Lipton RB, Hamelsky SW, Kolodner KB, Steiner TJ, Stewart WF. Migraine, quality of life, and depression: a population-based case-control study. Neurology. 2000;55:629-635.
3. Hu XH, Markson LE, Lipton RB, Stewart WF, Berger ML. Burden of migraine in the United States: disability and economic costs. Arch Intern Med. 1999;159: B83-B18.
4. Lipton RB, Stewart WF, Diamond S, Diamond ML, Reed M. Prevalence and burden of migraine in the United States: data from the American Migraine Study II. Headache. 2001;41:646-657.
5. Brandes JL. Global trends in migraine care: results from the MAZE survey. CNS Drugs. 2002;16(suppl 1): 13-18.
6. Henry P, Auray JP, Gaudin AF, et al. Prevalence and clinical characteristics of migraine in France. Neurology. 2002;59:232-237.
7. Martin S. Prevalence of migraine headache in Canada [letter]. CMAJ. 2001;164:1481.
8. Stewart WF, Shechter A, Rasmussen BK. Migraine prevalence: a review of population-based studies. Neurology. 1994;44:S17-S23.
9. Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2000;55:754-762.
10. Limmroth V, Katsarava Z, Fritsche G, Przywara S, Diener HC. Features of medication overuse headache following overuse of different acute headache drugs. Neurology. 2002;59:1011-1014.
11. McElroy SL, Arnold LM, Shapira NA, et al. Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial. Am J Psychiatry. 2003;160:255-261.
12. Hoopes SP, Reimherr FW, Hedges DW, et al. Treatment of bulimia nervosa with topiramate in a randomized, double-blind, placebo-controlled trial, part 1: improvement in binge and purge measures. J Clin Psychiatry. 2003;64:1335-1341.
13. Connor GS. A double-blind placebo-controlled trial of topiramate treatment for essential tremor. Neurology. 2002;59:132-134.
14. Galvez-Jimenez N, Hargreave M. Topiramate and essential tremor. Ann Neurol. 2000;47:837-838.
15. Shuaib A, Ahmed F, Muratoglu M, Kochanski P. Topiramate in migraine prophylaxis: a pilot study [abstract]. Cephalalgia. 1999;19:379-380.
16. Krusz JC, Scott V. Topiramate in the treatment of chronic migraine and other headaches [abstract]. Headache 1999;39:363.
17. Young WB, Hopkins MM, Shechter AL, Silberstein SD. Topiramate: a case series study in migraine prophylaxis. Cephalalgia 2002;22:659-663.
18. Edwards KR, Potter DL, Wu S-C, Kamin M, Hulihan J. Topiramate in the preventive treatment of episadic migraine: a combined analysis from pilot, double-blind, placebo-controlled trials. CNS Spectrums. 2003;8:428-432.
19. Shank RP, Gardocki JF, Streeter AJ, Maryanoff BE. An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia. 2000;41(suppl 1):S3-S9.
20. Storer RJ, Goadsby PJ. Topiramate inhibits trigeminovascular traffic in the cat: a possible locus of action in the prevention of migraine [abstract]. Neurology. 2003;60(suppl 1):A238-A239.
21. Tukey JW, Ciminera JL, Heyse JF. Testing the statistical certainty of a response to increasing doses of a drug. Biometrics. 1985;41:295-301.
22. Silberstein SD. Control of topiramate-induced paresthesias with supplemental Potassium [letter]. Headache. 2002;42:85.
23. Van Gaal L, Rissanen A, Wilding J, Vercruysse F, Perry B, Fitchet M. Efficacy and safety of topiramate in obese subjects [abstract]. Int J Obes. 2003;27 (suppl 1):S14.
24. Freitag FG, Collins SD, Carlson HA, et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology. 2002;58:1652-1659.
25. Tronvik E, Stovner U, Helde G, Sand T, Bovim G. Prophylactic treatment of migraine with an angiotensin II receptor blocker: a randomized controlled trial. JAMA. 2003;289:65-69.
26. Ramadan NM, Silberstein SD, Freitag FG, Gilbert TT, Frishberg BM. Evidence-based guidelines for migraine headache in the primary care setting: pharmacological management for prevention of migraine. Available at: http://www.aan.com/professionals/practice /pdfs/g10090.pdf. Accessed June 4, 2003.
27. Mathew NT, Saper JR, Silberstein SD, et al. Migraine prophylaxis with divalproex. Arch Neurol. 1995;52:281-286.
28. Klapper J. Divalproex sodium in migraine prophylaxis: a dose-controlled study. Cephalalgia. 1997;17:103-108.
29. International Headache Society Committee on Clinical Trials in Migraine. Guidelines for controlled trials of drugs in migraine: first edition. Cephalalgia. 1991;11:1-12.
30. Diamond S, Medina JL. Double blind study of propranolol for migraine prophylaxis. Headache. 1976;16:24-27.
31. Ziegler DK, Hurwitz A, Hassanein RS, Kodanaz HA, Preskorn SH, Mason J. Migraine prophylaxis: a comparison of propranolol and amitriptyline. Arch Neurol. 1987;44:486-489.
32. Pradalier A, Serratrice G, Collard M, et al. Long-acting propranolol in migraine prophylaxis: results of a double-blind, placebo-controlled study. Cephalalgia. 1989;9:247-253.
33. Gawel MJ, Kreeft J, Nelson RF, Simard D, Arnott WS. Comparison of the efficacy and safety of flunarizine to propranolol in the prophylaxis of migraine. Can J Neurol Sci. 1992;19:340-345.
34. Al-Qassab HK, Findley U. Comparison of propranolol LA 80 mg and propranolol LA 160 mg in migraine prophylaxis: a placebo controlled study. Cephalalgia. 1993;13:128-131.
35. Diener HC, Matias-Guiu J, Hartung E, et al. Efficacy and tolerability in migraine prophylaxis of flunarizine in reduced doses: a comparison with propranolol 160 mg daily. Cephalalgia. 2002;22:209-221.